Aspira Women's Health Narrows 9-Month Loss Amidst Delisting, Liquidity Woes

TL;DR

**AWHL is a high-risk bet, with ongoing losses and a 'going concern' warning; steer clear unless you're a speculative gambler.**

AI Summary

Aspira Women's Health Inc. (AWHL) reported a net loss of $4.892 million for the three months ended September 30, 2025, an increase from $3.547 million in the prior year, and a net loss of $9.411 million for the nine months ended September 30, 2025, an improvement from $11.706 million in the same period of 2024. Total revenue saw a slight increase, reaching $2.305 million for the quarter, up from $2.257 million, and $6.988 million for the nine months, up from $6.833 million. The company's gross profit improved to $1.383 million for the quarter and $4.477 million for the nine months. Operating expenses significantly decreased, falling from $5.099 million to $2.962 million for the quarter and from $16.837 million to $11.106 million for the nine months, primarily due to reductions in sales and marketing and general and administrative expenses. A substantial change in the fair value of warrant liabilities resulted in a $4.309 million expense for the quarter and a $4.012 million expense for the nine months, compared to income in the prior year. The company continues to face substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $540.808 million and negative cash flow from operations of $5.048 million for the nine months ended September 30, 2025. AWHL was delisted from Nasdaq on April 15, 2025, and now trades on the OTC QX Best Market.

Why It Matters

Aspira Women's Health's continued net losses and 'going concern' warning signal high risk for investors, despite a slight revenue increase. The delisting from Nasdaq to the OTC QX Market on April 17, 2025, significantly reduces liquidity and visibility, making it harder for investors to trade shares. For employees, the ongoing financial instability could lead to further cost-cutting measures, impacting job security and compensation. Customers relying on their diagnostic tests like OvaSuite may face uncertainty regarding long-term product availability and support if the company's financial health deteriorates further. In the competitive women's health diagnostics market, AWHL's struggles could open opportunities for more financially stable competitors.

Risk Assessment

Risk Level: high — The company explicitly states "substantial doubt about the Company's ability to continue as a going concern within one year" due to significant net losses, including $9.411 million for the nine months ended September 30, 2025, and negative cash flows from operations of $5.048 million for the same period. Additionally, AWHL was delisted from Nasdaq on April 15, 2025, further indicating severe financial distress and reduced market access.

Analyst Insight

Investors should exercise extreme caution and consider divesting any existing positions in AWHL due to the explicit 'going concern' warning and continued net losses. New investors should avoid initiating a position given the high financial risk and reduced liquidity from its delisting to the OTC QX Market.

Financial Highlights

debt To Equity

N/A

revenue

$6,988,000

operating Margin

-94.6%

total Assets

$7,296,000

total Debt

$11,640,000

net Income

-$9,411,000

eps

N/A

gross Margin

64.1%

cash Position

$3,809,000

revenue Growth

+2.3%

Revenue Breakdown

Key Numbers

• $9.411M — Net Loss (for the nine months ended September 30, 2025, an improvement from $11.706 million in 2024)
• $5.048M — Cash Used in Operations (for the nine months ended September 30, 2025, indicating ongoing cash burn)
• $540.808M — Accumulated Deficit (as of September 30, 2025, highlighting significant historical losses)
• $3.809M — Cash and Cash Equivalents (as of September 30, 2025, a critical liquidity metric)
• $6.988M — Total Revenue (for the nine months ended September 30, 2025, a slight increase from $6.833 million in 2024)
• $4.012M — Change in Fair Value of Warrant Liabilities (expense for the nine months ended September 30, 2025, a significant non-operating expense)
• 42,655,918 — Common Shares Outstanding (as of November 13, 2025, indicating potential dilution from equity offerings)
• $1.626M — Working Capital (as of September 30, 2025, a measure of short-term liquidity)
• $11.106M — Total Operating Expenses (for the nine months ended September 30, 2025, a significant reduction from $16.837 million in 2024)
• $2.5M — Nasdaq Minimum Stockholders' Equity (the threshold AWHL failed to meet, leading to delisting)

Key Players & Entities

• Aspira Women's Health Inc. (company) — registrant
• Nasdaq (regulator) — stock exchange from which AWHL was delisted
• OTC QX Market (regulator) — current stock exchange for AWHL
• BioReference Health, LLC (company) — marketing and distribution partner
• ARUP Laboratories (company) — marketing and distribution partner
• Ova1Plus (company) — product offered by Aspira Women's Health Inc.
• OvaWatch (company) — product offered by Aspira Women's Health Inc.
• OvaSuite (company) — collective name for diagnostic tests
• Aspira Synergy (company) — proprietary testing platform and cloud service
• Delaware (company) — state of incorporation for Aspira Women's Health Inc.

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has a substantial accumulated deficit of $540.808 million and negative cash flow from operations of $5.048 million for the nine months ended September 30, 2025. This raises substantial doubt about its ability to continue as a going concern.
• Nasdaq Delisting [high — regulatory]: AWHL was delisted from Nasdaq on April 15, 2025, for failing to meet the minimum stockholders' equity requirement of $2.5 million. Trading now occurs on the OTC QX Best Market, which may limit liquidity and investor access.
• Significant Warrant Liability Expense [medium — financial]: The company incurred a $4.309 million expense in the three months and $4.012 million in the nine months ended September 30, 2025, due to changes in the fair value of warrant liabilities. This contrasts with income recognized in the prior year and negatively impacts net income.
• Decreasing Operating Expenses [medium — operational]: While operating expenses decreased significantly from $16.837 million to $11.106 million for the nine months ended September 30, 2025, this was primarily driven by reductions in sales and marketing and general and administrative expenses, which could impact future growth initiatives.
• Increasing Net Loss [high — financial]: The net loss for the three months ended September 30, 2025, increased to $4.892 million from $3.547 million in the prior year, despite a slight revenue increase. The nine-month net loss improved to $9.411 million from $11.706 million, but remains substantial.
• Warrant Liability Valuation [medium — financial]: The substantial increase in warrant liabilities to $5.280 million as of September 30, 2025, from $60 as of December 31, 2024, indicates a significant change in the perceived value or terms of outstanding warrants, leading to non-cash expenses.

Industry Context

The women's health diagnostics market is evolving, with increasing demand for innovative solutions. However, companies in this sector often face challenges related to regulatory approvals, reimbursement policies, and the need for substantial R&D investment. Competition can be intense, with both established players and emerging startups vying for market share.

Regulatory Implications

The delisting from Nasdaq highlights the critical importance of meeting exchange listing requirements, particularly regarding financial health and equity levels. Continued operation on OTC markets may affect investor perception and access to capital. Compliance with healthcare regulations and data privacy laws remains paramount.

What Investors Should Do

1. Monitor cash burn and liquidity closely.
2. Evaluate the impact of warrant liability fluctuations.
3. Assess the sustainability of reduced operating expenses.
4. Consider the implications of OTC trading.

Key Dates

• 2025-04-15: Delisted from Nasdaq — Indicates failure to meet listing requirements, potentially impacting stock liquidity and investor confidence.
• 2025-09-30: End of Q3 2025 Reporting Period — Financial results for the quarter and nine months ending this date are reported, showing increased net loss and significant warrant liability expenses.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (AWHL has a substantial accumulated deficit of $540.808 million, indicating significant historical unprofitability.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least 12 months. (The company's financial condition raises substantial doubt about its ability to continue as a going concern.)

Fair Value of Warrant Liabilities

The estimated market value of outstanding warrants, which can fluctuate based on factors like stock price and time to expiration. (Changes in fair value resulted in significant non-cash expenses for AWHL in the reported periods.)

OTC QX Best Market

A quotation service for over-the-counter (OTC) securities, generally for companies that do not meet the listing requirements of major exchanges. (AWHL now trades on this market after being delisted from Nasdaq.)

Operating Expenses

Costs incurred by a company in its normal business operations, excluding cost of goods sold. (AWHL significantly reduced operating expenses, primarily in sales and marketing and G&A, for the nine months ended September 30, 2025.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Aspira Women's Health Inc. reported a slight revenue increase to $6.988 million from $6.833 million in the prior year, accompanied by a significant reduction in total operating expenses from $16.837 million to $11.106 million. Despite these operational improvements, the net loss widened to $4.892 million for the quarter, and the company incurred substantial expenses related to the fair value of warrant liabilities, which were income-generating in the prior year. The company's financial position remains precarious, with a large accumulated deficit and ongoing cash burn, leading to continued going concern warnings.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share AWHL The OTC QX Market I

Filing Documents

• awhl-20250930x10q.htm (10-Q) — 1790KB
• awhl-20250930xex31d1.htm (EX-31.1) — 12KB
• awhl-20250930xex31d2.htm (EX-31.2) — 12KB
• awhl-20250930xex32d1.htm (EX-32.1) — 9KB
• 0000926617-25-000008.txt ( ) — 8816KB
• awhl-20250930.xsd (EX-101.SCH) — 57KB
• awhl-20250930_cal.xml (EX-101.CAL) — 56KB
• awhl-20250930_def.xml (EX-101.DEF) — 258KB
• awhl-20250930_lab.xml (EX-101.LAB) — 529KB
• awhl-20250930_pre.xml (EX-101.PRE) — 379KB
• awhl-20250930x10q_htm.xml (XML) — 1604KB

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Changes in Stockholders' Deficit for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 5 Notes to Condensed Consolidated Financial Statements 6 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 41 Item 4

Controls and Procedures

Controls and Procedures 41 PART II Other Information 43 Item 1

Legal Proceedings

Legal Proceedings 43 Item 1A

Risk Factors

Risk Factors 43 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 43 Item 3 Defaults Upon Senior Securities 43 Item 4 Mine Safety Disclosures 43 Item 5 Other Information 43 Item 6 Exhibits 44

SIGNATURES

SIGNATURES 45 The following are registered and unregistered trademarks and service marks of Aspira Women's Health Inc.: VERMILLION SM , ASPIRA WOMEN'S HEALTH , OVA1 , OVERA , ASPIRA LABS , OVACALC , OVASUITE SM , ASPIRA GENETIX SM , OVA1PLUS , OVAWATCH , ENDOCHECK SM , ENDOINFORM TM , OVAINFORM TM , OVAINHERIT SM , ASPIRA SYNERGY , OVA360 SM , ASPIRA IVD SM , AND YOUR HEALTH, OUR PASSION . i Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Aspira Women's Health Inc. Condensed Consolidated Balance Sheets (unaudited) (Amounts in Thousands, Except Share and Par Value Amounts) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 3,809 $ 1,769 Accounts receivable, net of reserves of $ 0 1,317 990 Prepaid expenses and other current assets 417 1,098 Inventories 282 326 Total current assets 5,825 4,183 Property and equipment, net 44 69 Intangible assets, net 343 - Right-of-use assets 1,029 1,194 Other assets 55 45 Total assets $ 7,296 $ 5,491 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable $ 1,811 $ 2,173 Accrued liabilities 1,967 2,445 Current portion of long-term debt 234 229 Short-term debt - 614 Current maturities of lease liabilities 187 7 Total current liabilities 4,199 5,468 Non-current liabilities: Long-term debt 1,100 1,278 Non-current maturities of lease liabilities 1,061 1,248 Warrant liabilities 5,280 60 Total liabilities 11,640 8,054 Commitments and contingencies (Note 5) Stockholders' deficit: Preferred stock, par value $ 0.001 per share, 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2025 and December 31, 2024 - - Common stock, par value $ 0.001 per share, 200,000,000 shares authorized at September 30, 2025 and December 31, 2024; 42,655,918 and 17,407,120 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 43 17 Additional paid-in capital 536,421 528,817 Accumulated deficit ( 540,808 ) ( 531,397 ) Total stockholders' deficit ( 4,344 ) ( 2,563 ) Total liabilities and stockholders' deficit $ 7,296 $ 5,491 See accompanying notes to the unaudited condensed consolidated financial statements. 1 Table of Contents Aspira Women's Health Inc. Condensed Consolidated Statements of Operation

View Full Filing

View this 10-Q filing on SEC EDGAR